Elevance Health ELV 深 滬
已收盤 11-06 16:00:00 美东时间
425.62
-6.380
-1.48%
華盛通- 最 高430.69
- 今 開421.47
- 成交量 144.39万股
- 最 低 421.47
- 昨 收 432.00
- 總市值 919.58亿
- 52周最高 450.69
- 市盈率 靜 16.88
- 換手率 0.67%
- 52周最低 269.68
- 委 比 -60.00%
- 總股本 2.16亿
- 歷史最高 552.00
- 量 比 0.88
- 振 幅 2.13%
- 歷史最低 -0.615
- 每 手 1
- 風險率 43.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅94.37%！摩根士丹利上调西部数据(WDC)目标价至668美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持西部数据"超配"评级，目标价从643美元升至668美元；摩根大通：维持西部数据"超配"评级，目标价从600美元升至650美元
10-26 12:30
美股大行评级 | 潜在涨幅109.52%！富国银行上调Helus Pharma目标价至22美元，维持"超配"评级
今日重点评级关注：富国银行：维持Helus Pharma"超配"评级，目标价从16美元升至22美元；美银证券：维持SpaceX"买入"评级，目标价从235美元升至275美元
10-23 12:30
财报速睇 | Elevance Health 2026财年Q3营收514.29亿美元，同比增长1.4%；归母净利润13.65亿美元，同比增长14.8%
华盛资讯10月22日讯，Elevance Health公布2026财年Q3业绩，公司Q3营收514.29亿美元，同比增长1.4%，归母净利润13.65亿美元，同比增长14.8%。
10-22 02:31
财报速睇 | Elevance Health 2026财年Q3营收514.29亿美元，同比增长1.4%；归母净利润13.65亿美元，同比增长14.8%
华盛资讯10月21日讯，Elevance Health公布2026财年Q3业绩，公司Q3营收514.29亿美元，同比增长1.4%，归母净利润13.65亿美元，同比增长14.8%。
10-21 18:16
Elevance Health FY2026 Adj EPS expected to be more than $29.00 vs $27.23 Est
Elevance Health (NYSE:ELV) FY2026 expected to be more than $29.00 vs $27.23 Est..
10-21 18:02
Elevance Health FY2026 GAAP EPS expected to be more than $22.00 vs $20.74 Est
Elevance Health (NYSE:ELV) FY2026 expected to be more than $22.00 vs $20.74 Est..
10-21 18:02
Elevance Health Q3 Adj. EPS $6.99 Beats $4.68 Estimate, Sales $50.440B Beat $49.213B Estimate
Elevance Health (NYSE:ELV) reported quarterly earnings of $6.99 per share which beat the analyst consensus estimate of $4.68 by 49.36 percent. This is a 15.92 percent increase over earnings of $6.03 per share from the same period last year. The company reported quarterly sales of $50.440 billion whi...
10-21 18:01
Elevance Health Q3 2026 Earnings: Carelon Growth Supports Higher Guidance
Elevance Health’s Q3 2026 operating revenue rose 0.7% to $50.44 billion, while diluted EPS increased 17.9% to $6.27 and adjusted diluted EPS climbed 15.9% to $6.99. Carelon delivered higher revenue, profit, and margins, but Health Benefits operating gain fell 27.5% as targeted investments weighed on results despite an improved benefit expense ratio. Quarterly operating cash flow reached $1.3 billion. Elevance Health raised full-year diluted EPS g
10-21 10:12
美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
